Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Harvard Business School
Citi
Deloitte
Cerilliant
Colorcon
Chubb
Healthtrust
McKinsey

Generated: April 19, 2018

DrugPatentWatch Database Preview

RELISTOR Drug Profile

« Back to Dashboard

When do Relistor patents expire, and when can generic versions of Relistor launch?

Relistor is a drug marketed by Salix Pharms and Salix Pharms Inc and is included in two NDAs. There are eleven patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and twelve patent family members in thirty-six countries.

The generic ingredient in RELISTOR is methylnaltrexone bromide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methylnaltrexone bromide profile page.
Summary for RELISTOR
International Patents:112
US Patents:11
Applicants:2
NDAs:2
Suppliers / Packagers: 1
Bulk Api Vendors: 26
Clinical Trials: 12
Patent Applications: 727
Drug Prices:see details
DailyMed Link:RELISTOR at DailyMed
Drug patent expirations by year for RELISTOR
Pharmacology for RELISTOR
Ingredient-typeQuaternary Ammonium Compounds
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Synonyms for RELISTOR
(1S,5R,13R,17S)-4-(CYCLOPROPYLMETHYL)-10,17-DIHYDROXY-4-METHYL-14-OXO-12-OXA-4-AZAPENTACYCLO[9.6.1.0(1),(1)(3).0?,(1)?.0?,(1)?]OCTADECA-7(18),8,10-TRIEN-4-IUM
(1S,5R,13R,17S)-4-(CYCLOPROPYLMETHYL)-10,17-DIHYDROXY-4-METHYL-14-OXO-12-OXA-4-AZAPENTACYCLO[9.6.1.0(1),(1)(3).0?,(1)?.0?,(1)?]OCTADECA-7(18),8,10-TRIEN-4-IUM BROMIDE
(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one
(5|A)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium Bromide
1356447-13-6
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinanium-6-one
17-(cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium bromide
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium
3844AH
73232-52-7
77061-EP2305652A2
77061-EP2308509A1
83387-25-1
AKOS015896214
AN-37324
BDBM50278337
C21H26NO4.Br
CHEBI:136007
CHEMBL1186579
CHEMBL1201770
CHEMBL470617
CHIR-01020
CS-0762
CTK3E8491
D03YVO
D06618
D0A6EE
GTPL7563
HY-75766
I06-1616
IFGIYSGOEZJNBE-KNLJMPJLSA-N
JVLBPIPGETUEET-GAAHOAFPSA-O
Methylnaltrexone
Methylnaltrexone (Bromide)
Methylnaltrexone bromide
Methylnaltrexone bromide (JAN/USAN)
Methylnaltrexone bromide, >=97% (HPLC)
Methylnaltrexone bromide, United States Pharmacopeia (USP) Reference Standard
Methylnaltrexonium
MNTX
MNTX-302
MOA-728
Morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, (5alpha)-
MRZ 2663BR
MRZ-2663BR
N-Cyclopropylmethyl-noroxymorphone Methobromide
N-Methyl Naltrexone Bromide
N-Methylnaltrexone
N-Methylnaltrexone Bromide
Naltrexone MB
Naltrexone methobromide
Naltrexone Methyl Bromide
ONO-3849
PL008834
PL071389
Quaternary ammonium naltrexone
Relistor (TN)
SCHEMBL2798188
SCHEMBL49356
ST51053157
W-5330
ZINC5764759

US Patents and Regulatory Information for RELISTOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-003 Sep 27, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for RELISTOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for RELISTOR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 150 mg ➤ Subscribe 2016-09-06
➤ Subscribe Injection 8 mg/0.4 mL ➤ Subscribe 2015-09-08
➤ Subscribe Injection 12 mg/0.6 mL ➤ Subscribe 2015-07-22

Non-Orange Book US Patents for RELISTOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,455,644 Peripheral opioid receptor antagonists and uses thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Deloitte
Teva
AstraZeneca
Farmers Insurance
Chinese Patent Office
Johnson and Johnson
UBS
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.